| Entries |
| Document | Title | Date |
|---|
| 20080214785 | HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.” | 09-04-2008 |
| 20080319170 | Methods and Uses of Antibodies in the Purification of Interferon - The present invention provides improved methods and uses of an immunoglobulin in the purification of an interferon composition. The methods of the invention provide for the use of a monoclonal antibody in the purification of an interferon composition comprising a plurality of interferon alpha subtypes. The use of the monoclonal antibody provides for the production of an interferon composition with a consistent proportion of interferon subtypes, providing a resulting improvement in simplicity of production of the resulting interferon composition. | 12-25-2008 |
| 20090030183 | Interferon Beta-Like Molecules - The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide. | 01-29-2009 |
| 20090036651 | Purification of proteins - The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed. | 02-05-2009 |
| 20090036652 | PURIFICATION OF PROTEINS USING PREPARATIVE REVERSE PHASE CHROMATOGRAPHY (RPC) - The present invention provides a method for industrial-scale protein separation by reverse phase chromatography by use of a buffer system and an additional salt. | 02-05-2009 |
| 20090043076 | Modified interferon beta with reduced immunogenicity - The present invention relates a modified human interferon beta (INFβ) which is less immunogenic than human INFβ (SEQ ID NO: 1) when administered in vivo to a human. The modified human INFβ comprises an amino acid residue sequence that differs from SEQ ID NO: 1 by an amino acid residue substitution selected from the group consisting of L57A, L57C, L57D L57E, L57G, L57H, L57K, L57N, L57P, L57Q, L57R, L57S, and L57T and an additional substitution selected from the group consisting of the H140A, H140C, H140G, and H140P. | 02-12-2009 |
| 20090054627 | PROCESS FOR THE PURIFICATION OF IL-18 BINDING PROTEIN - The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid using aqueous two-phase partitioning. | 02-26-2009 |
| 20090054628 | METHOD AND SYSTEM FOR IN VITRO PROTEIN FOLDING - A method of recovering a refolded protein involves static mixing a concentrated solution of a denatured protein with a refolding diluent to obtain the refolded protein. The method is particularly suitable for microbially produced recombinant proteins in large processing volumes. The denatured protein solution can be obtained by isolating protein from the microbial host and exposing them to a denaturant. This solution is mixed with a suitable refolding diluent under static mixing conditions compatible with proper folding of the protein so that the refolded protein is obtained, preferably rapidly and with high yield. A system for implementing the refolded protein recovery method includes a static mixer, a conduit inline with and upstream from the static mixer, and an inlet to the conduit upstream of the static mixer, and optionally a dynamic, preferably non-turbulent, mixing vessel downstream from the static mixer. The invention finds particular use in large scale production of proteins, particularly recombinant proteins. | 02-26-2009 |
| 20090099336 | CA6 Antigen-Specific Cytotoxic Conjugate and Methods of Using the Same - Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof. | 04-16-2009 |
| 20090105455 | Purified interleukin-15/fc fusion protein and preparation thereof - The present invention relates to a process for purifying an interleukin-15/Fc fusion protein from a composition, which process comprises a) applying the composition to an affinity chromatography column and eluting a first IL-15/Fc eluate from the column and b) applying the eluate of step a) to an ion exchange chromatography column and eluting a second IL-15/Fc eluate from the column; and to a purified interleukin-15/Fc fusion protein and a composition, in particular a pharmaceutical composition, comprising such a fusion protein. | 04-23-2009 |
| 20090198043 | FELINE IL-18 PROTEINS - The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules encoding such proteins, antibodies raised against such proteins and/or inhibitors of such proteins or nucleic acid molecules. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and/or inhibitors, as well as their use to evaluate and regulate an immune response in an animal. | 08-06-2009 |
| 20090270595 | IL-1 RELATED POLYPEPTIDES - The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 10-29-2009 |
| 20090281281 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF - Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications. | 11-12-2009 |
| 20090286958 | INTERFERON-BETA FUSION PROTEINS AND USES - A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described. | 11-19-2009 |
| 20090299037 | METHODS OF PURIFYING PROTEINS FROM EGG WHITE - The invention provides methods of purifying proteins, e.g., cytokines, from egg whites. | 12-03-2009 |
| 20100004428 | Method of Preparing Propionic Acid-Terminated Polymers - The invention provides methods for preparing polymers bearing a terminal propionic acid. The method involves first reacting a water soluble and non-peptidic polymer comprising at least one hydroxyl group with a tertiary alkyl acrylate in the presence of a catalyst to form a propionic acid ester of the polymer, wherein the polymer has a weight average molecular weight of at least about 10,000 Da; and then treating the propionic acid ester of the polymer with a strong acid to form a propionic acid of the polymer. | 01-07-2010 |
| 20100029906 | Synthetic mimics of mammalian cell surface receptors: method and compositions - The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed. | 02-04-2010 |
| 20100029907 | PEPTIDE-POLYMER CONJUGATES - This invention relates to a conjugate of a polymer moiety and an interferon-β moiety, an erythropoietin moiety, or a growth hormone moiety. | 02-04-2010 |
| 20100036097 | Mutant Interleukin-2 (IL-2) Polypeptides - The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα. | 02-11-2010 |
| 20100048872 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins. | 02-25-2010 |
| 20100081789 | Novel Vectors for Production of Interferon - Novel compositions for the production of interferons such as interferon-α 2a, interferon-α 2b, or interferon-β 1a (IFN-α 2a, IFN-α 2b, or IFN-β 1a) are provided. The compositions comprise components of vectors, such as a vector backbone, a promoter, and a gene of interest that encodes an interferon such as IFN-α 2a, IFN-α 2b, or IFN-β 1a, and the vectors comprising these components. In certain embodiments, these vectors are transposon-based vectors. Also provided are methods of making these compositions and methods of using these compositions for the production of an interferon such as IFN-α 2a, IFN-α 2b, or IFN-β1a. | 04-01-2010 |
| 20100093976 | USE OF INTERLEUKIN-11 AS THERAPEUTIC AGENT FOR HEART DISEASE - The present invention demonstrates the myocardial protective effects of interleukin 11 in vivo, and provides preventive, therapeutic, or other types of drugs for heart disease using interleukin 11 as the active ingredient. The present invention, by utilizing the myocardial protective effects of interleukin 11, can suppress the progress of myocardial injury, prevent the onset of heart failure, or suppress the progress of heart failure. | 04-15-2010 |
| 20100099850 | HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.” | 04-22-2010 |
| 20100099851 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME - The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, a protease-resistant polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof. | 04-22-2010 |
| 20100105869 | Physiologically Active Polypeptide Conjugate Having Prolonged In Vivo Half-Life - A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response. | 04-29-2010 |
| 20100105870 | Method Of Complexing A Protein By The Use Of A Dispersed System And Proteins Thereof - The present invention relates to methods for complexing a protein in a dispersed medium. Also disclosed are associated proteins produced by the methods of complexing of the present invention. Pharmaceutically effective stabilized protein dosages are also disclosed. The present invention also relates to a method for associating AHF protein in a dispersed medium. | 04-29-2010 |
| 20100121032 | LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME - Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin. | 05-13-2010 |
| 20100145017 | METHOD OF PRODUCING INTERFERON-B COMPLEX - A method for producing an interferon-β complex includes binding interferon-β to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, sugar alcohols thereof, and C | 06-10-2010 |
| 20100210821 | PROCESS FOR ISOLATION AND PURIFICATION OF A TARGET PROTEIN FREE OF PRION PROTEIN (PRPSC) - A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrP | 08-19-2010 |
| 20100222552 | PRODUCTION AND PURIFICATION OF IL-29 - The expression vectors and methods using an | 09-02-2010 |
| 20100261885 | PEGylation by the Dock and Lock (DNL) Technique - The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases. | 10-14-2010 |
| 20110034672 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES - The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second chromatography step is not a hydroxylapatite chromatography step in case of polypeptides with an isoelectric point below 6.0, and the third chromatography step can be performed in flow-through mode with polypeptides having a low or high isoelectric point. | 02-10-2011 |
| 20110060128 | PROCESS FOR THE PURIFICATION OF INTERLEUKIN-4 AND ITS MUTEINS - This invention relates generally to a method for purifying Interleukin-4 or related variants from an | 03-10-2011 |
| 20110082283 | MULTIMERIC ELP FUSION CONSTRUCTS - ELP fusion proteins, multimeric ELP spider complexes formed of ELP fusion proteins, and methods of using the same. The construct may be in the form of an ELP spider structure complex including multi-leg moieties comprising ELP fusion proteins capable of forming covalent disulfide bonds. The multimeric fusion constructs may be employed in peptide production and purification and/or to enhance proteolytic resistance of a protein or peptide moiety in a fusion construct, by provision of the fusion protein in an ELP spider complex. | 04-07-2011 |
| 20110087007 | Cytokine-Like Proteins - A full-length cDNA corresponding to an EST (AA418955), which does not show any homology to other proteins in the database but has a weak homology to G-CSF, has been successfully isolated by synthesizing primers based on the EST sequence, and effecting PCR-cloning from a human fetal spleen library. Sequencing of the thus-isolated cDNA and analysis of its structure revealed that the cDNA has typical characteristics of a factor belonging to the IL-6/G-CSF/MGF family. It is also found out that the culture supernatant of said sequence-transfected CHO cells shows a proliferation supporting activity towards bone marrow cells in the coexistence of kit ligand. | 04-14-2011 |
| 20110105723 | Method of Detecting Malignancy of Nasopharyngeal Carcinoma and A Nasopharyngeal Carcinoma Malignancy Biomarker - A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3α expression level. Then, the MIP-3α expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3α expression level between the specimen and the control. | 05-05-2011 |
| 20110112277 | Stabilized Polymeric Thiol Reagents - Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y—S—W] | 05-12-2011 |
| 20110144305 | GAG BINDING PROTEIN - A method is provided for introducing a GAG binding site into a protein comprising the steps:
| 06-16-2011 |
| 20110144306 | LIGATION OF STAPLED POLYPEPTIDES - The present invention provides technology for making large (e.g., greater than 50 amino acids), semi-synthetic, stapled or stitched proteins. The method essentially involves ligating a synthetically produced stapled or stitched peptide to a larger protein. Modified version of IL-13 and MYC are provided as illustrative examples. | 06-16-2011 |
| 20110178275 | INDUSTRIAL PLANT-BASED PRODUCTION OF ANIMAL-FREE RECOMBINANT PROTEINS IN DEFINED ENVIRONMENT - The present invention provides improved methods for animal-free protein production of high-value heterologous proteins produced in plants, plant derived tissue or plant cells. The invention reduces costs and increases the speed of manufacturing of active ingredients in transgenic plants. Furthermore, the invention improves the quality and safety of heterologous proteins produced in plants. The enhanced control of conditions in manufacturing of heterologous industrial and biopharmaceutical heterologous proteins obtained by the present invention with the combination of soil-less, hydroponic culture on conveyor belts with distinct nutrient zones in soilless greenhouses improves greatly the consistency of protein production in transgenic plants and conformity with quality control procedures applied for the manufacturing of active ingredients by the pharmaceutical industry, cosmetic industry, fine chemicals industry and veterinary industry. | 07-21-2011 |
| 20110190476 | Compositions And Methods For Regulation Of Tumor Necrosis Factor-Alpha - The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression. | 08-04-2011 |
| 20110218325 | Inhibitor of Endogenous Human Interferon-Gamma - Inactivated protein derivatives of the hIFN-γ that preserve affinity to the hIFN-γ receptor are useful in the treatment of autoimmune diseases, especially multiple sclerosis. | 09-08-2011 |
| 20110224407 | Type I Interferon Antagonists - Disclosed in certain embodiments is a method of preparing a Type 1 interferon antagonist comprising modifying a Type 1 interferon at the site of interaction with the interferon receptor subunit IFNAR-1 such that the binding affinity of the interferon to the IFNAR-1 subunit is reduced as compared to the native interferon, and corresponding compositions and methods of treatment thereof. | 09-15-2011 |
| 20110257366 | Method for screening candidate compounds for antitumor drug - Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index. | 10-20-2011 |
| 20110257367 | ALLOGENEIC VACCINE AND METHODS TO SYNTHESIZE SAME - This invention provides a genetically manipulated cell useful for treating or preventing a malignant tumor in a patient which: (a) expresses at least one immunomolecule selected from the group consisting of cytokines, adhesion molecules, costimulatory factors, tumor associated antigens and tumor specific antigens; and (b) is allogeneic to the patient. This invention also provides a method of treating a malignant tumor in a subject which comprises administering to the subject a plurality of the genetically manipulated cell so as to inhibit proliferation of the malignant tumor. This invention further provides a method of preventing tumor formation in a subject comprising administering to the subject a plurality of the genetically manipulated cell so as to prevent tumor formation. Finally, this invention provides a method for making the genetically manipulated cell. | 10-20-2011 |
| 20110257368 | PURIFICATION OF RECOMBINANTLY PRODUCED INTERFERON - The present invention provides a method for separating desired interferon isoforms from undesired interferon isoforms that involves subjecting the isoforms to anion exchange column chromatography and a biphasic elution procedure. A strong elution solution is used in the first elution phase to facilitate elution of the desired isoform from the column and a weak elution solution is used in the second phase to suppress elution of the desired isoforms. | 10-20-2011 |
| 20110306752 | MUTANT INTERLEUKIN-2 (IL-2) POLYPEPTIDES - The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα. | 12-15-2011 |
| 20110306753 | Method for Increasing Protein Expression in Cells - The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermore, it relates to nucleic acid sequences exhibiting a reduced number of RNase L cleavage sites as well as to the proteins translated from such sequences. | 12-15-2011 |
| 20120016104 | GLYCOSYLATED IL-7, PREPARATION AND USES - The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects. | 01-19-2012 |
| 20120035347 | INTERFERON-ALFA SENSITIVITY BIOMARKERS - The present invention provides biomarkers of sensitivity to interferon alfa (IFN-α). These IFN-α sensitivity biomarkers are useful, inter alia, to identify patients who are most likely to benefit from treatment with pharmaceutical compositions of IFN-α, in methods of treating patients having a disease susceptible to treatment with interferon alfa, and in methods for selecting the most appropriate therapy for such patients. | 02-09-2012 |
| 20120088904 | ANALYSIS OF HCV GENOTYPES - A method for predicting response of a patient infected with HCV-1a to interferon treatment | 04-12-2012 |
| 20120116054 | CONCENTRATED PROTEIN LYOPHILATES, METHODS, AND USES - The invention provides, among other things, lyophilized compositions of high surface area that comprise a protein and that reconstitute quickly and efficiently to solution of high protein concentration with minimal formation, if any, of foam, effervescence, bubbles, turbidity, or particulates that might be deleterious. The invention also provides, among other things, methods for making the lyophilized compositions. The invention in additional aspects also provides Raman Imaging Spectrographic methods for real time analyses of polymorphs in a sample using PLS algorithms. By way of particular example, the use of the method for the analysis of mannitol polymorphs is described, and the use of the analysis to determine optimum compositions and lyophilization methods for producing lyophilates of pharmaceutical proteins having a predefined distribution of mannitol polymorphs and having the aforementioned reconstitution properties is also described. | 05-10-2012 |
| 20120142896 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES - Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided. | 06-07-2012 |
| 20120165508 | FUSION PROTEINS THE PROCESS TO PREPARATION AND UTILIZATION IN EXPRESSION SYSTEMS OF RECOMBINANT PROTEINS - The invention relates to fusion proteins comprising an amino acid sequence corresponding to an H fragment or an amino acid sequence corresponding to a calcium binding protein excreted-secreted by the adult worm of | 06-28-2012 |
| 20120197006 | MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES - Modified interferon beta polypeptides and uses thereof are provided. | 08-02-2012 |
| 20120245325 | SPLICE VARIANTS OF HUMAN IL-23 RECEPTOR (IL-23R) mRNA AND USE OF A DELTA9 ISOFORM IN PREDICTING INFLAMMATORY BOWEL DISEASES - There is disclosed the cloning and identification of human IL-23R splice variants caused by alternative splicing of the IL-23R mRNA in human. Alternative mRNA forms occur through skipping one, multiple full exons or partial exons, within the IL-23R gene. A total of twenty-five (25) different IL-23R transcripts were identified. A novel exon deletion (exon 9) isoform in the interleukin 23 receptor is disclosed, denoted as Δ9. The present application also describes a quantitative assay to measure different IL-23R isoform. Detection of Δ9 isoform of IL-23R is predominantly present in colon and cervical tissues. A decrease in Δ9 is observed in inflamed colon tissues in Crohn's patients. There is disclosed a method of predicting Crohn's disease by measuring Δ9 isoform of IL-23R. | 09-27-2012 |
| 20120271037 | PRODUCTION AND PURIFICATION OF IL-29 - The expression vectors and methods using an | 10-25-2012 |
| 20120302733 | SELECTION AND CHARACTERIZATION OF NOVEL PLANT-DERIVED RECOMBINANT HUMAN INTERFERONS WITH BROAD SPECTRUM ACTIVITY - Methods to derive novel hybrid type 1 interferons that are broadly active against highly pathogenic viruses of biodefense significance are described. Libraries of hybrid interferon genes were produced using gene shuffling, the proteins were expressed, and screened for activity against viruses of interest. Sequences of several broadly active hybrid interferons are described. | 11-29-2012 |
| 20120316322 | DESIGN AND USE OF NEW RECOMBINANT INTERFERONS WITH ALTERED SPATIAL CONFIGURATION AND THREE-DIMENSIONAL STRUCTURE - This invention provides a crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-α2 | 12-13-2012 |
| 20130096279 | PROCESS FOR THE PURIFICATION OF A GROWTH FACTOR PROTEIN - A process of purifying a Growth Factor Protein in a purification sequence employing chromatography characterized in that
| 04-18-2013 |
| 20130116410 | NEW STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS - A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa. | 05-09-2013 |
| 20130150555 | COMPOSITION CONTAINING INDUCER OF SIRT1 EXPRESSION FOR PREVENTING OR TREATING SEPSIS OR SEPTIC SHOCK - The present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock. The inducer of SIRT1 expression can remarkably reduce the mortality caused by sepsis or septic shock by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines. Therefore, the inducer of SIRT1 expression is useful for preventing or treating sepsis or septic shock. | 06-13-2013 |
| 20130184437 | DESIGN AND USE OF NEW RECOMBINANT INTERFERONS WITH ALTERED SPATIAL CONFIGURATION AND THREE-DIMENSIONAL STRUCTURE - This invention provides a crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-α2 | 07-18-2013 |
| 20130190478 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES - The current invention reports a method for the purification of a non-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second chromatography step is not a hydroxylapatite chromatography step in case of polypeptides with an isoelectric point below 6.0, and the third chromatography step can be performed in flow-through mode with polypeptides having a low or high isoelectric point. | 07-25-2013 |
| 20130237689 | SOLUBLE HLA CLASS II COMPLEXES AND METHODS OF PRODUCTION AND USE THEREOF - The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein. | 09-12-2013 |
| 20130253170 | HYALURONIC ACID-PROTEIN CONJUGATE AND METHOD FOR PREPARING SAME - An HA-protein conjugate in which an HA-aldehyde derivative, in which an aldehyde group is introduced to a hyaluronic acid or a salt thereof, is conjugated to the N-terminus of a protein, and a method for preparing the same are provided. The HA-protein conjugate includes a protein drug exhibiting an excellent bioconjugation efficiency and long-term medicinal effects, and has excellent protein drug activities since the hyaluronic acid is specifically conjugated to the N-terminus of the protein. Also, since liver-targeting properties of the hyaluronic acid can be freely controlled by changing an aldehyde substitution rate of the HA-aldehyde derivative, the HA-protein conjugate can be effectively used as a protein drug for treating liver diseases, and also be useful in enabling long-term medicinal effects of a protein drug required to bypass the liver. Accordingly, the HA-protein conjugate can be effectively used for a drug delivery system of proteins. | 09-26-2013 |
| 20130281667 | USES OF SPATIAL CONFIGURATION TO MODULATE PROTEIN FUNCTION - This invention provides a set of methods for modulating protein spatial configuration. First, select the amino-acid codon for encoding the target protein according to host codon usage. Second, choose combinations which can modulate the spatial configuration and construct into different vectors which can transfect a series of hosts. Third, choose the vector promoter by monitoring a combination of base pairs after combining the code sequence of the promoter and the target protein. Finally, choose the appropriate expression host to express the target protein, refold and purify, measure the activity and spatial configuration. | 10-24-2013 |
| 20130331549 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom - The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance. | 12-12-2013 |
| 20140005361 | FC-Interferon-Beta Fusion Proteins | 01-02-2014 |
| 20140024806 | Glycoproteins Produced in Plants and Methods of Their Use - Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed. | 01-23-2014 |
| 20140039158 | POLYMERIC CONJUGATES AND METHODS OF PREPARING THE SAME - Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the N-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a Lysine or a Histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the N-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the N-terminal of the target. | 02-06-2014 |
| 20140046026 | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 - Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response. | 02-13-2014 |
| 20140094588 | PROGNOSTIC AND THERAPEUTIC SIGNATURE FOR MALIGNANT MELANOMA - The present invention relates to a method of predicting the course of disease in a patient having a malignant melanoma, the method comprising determining in melanoma cells comprised in a sample obtained from said malignant melanoma the presence or amount of at least five biomarkers selected from the group comprising or consisting of MTAP, PTEN, Bax, Bcl-X, β-Catenin, CD20, Cox-2, CD49d and MLH1, wherein the absence or decreased amount of MTAP and β-Catenin and/or the presence or increased amount of PTEN, Bax, Bcl-X, CD20, Cox-2, CD49d and MLH1, is associated with a disadvantageous course of disease. | 04-03-2014 |
| 20140135479 | POLYPEPTIDE ADJUVANT COMPOSITION WITH THERMOSTABILITY AND MANUFACTURE THEREOF - The present invention provides a polypeptide adjuvant composition with thermostability, which is designed from wild-type chicken interleikin-1β to construct a new chicken interleikin-1β, named CP-interleikin-1β. The CP-interleikin-1β having improved heat resistance keeps the original biological activity, and which helps to develop protein adjuvant with high efficiency and uses in medical application. The present invention also provides a method of manufacturing such polypeptide adjuvant composition. | 05-15-2014 |
| 20140142283 | METHOD FOR SEPARATION OF MONOMERIC POLYPEPTIDES FROM AGGREGATED POLYPEPTIDES - The present invention relates to methods for obtaining a polypeptide in a monomeric form, the method comprising a) providing a solution containing the polypeptide in monomeric form and in aggregated form, wherein the ratio of monomeric to aggregated form is 4:1 or less, as determined by size exclusion chromatography, b) performing mixed-mode chromatography in bind-and-elute mode, or hydrophobic interaction chromatography in flow-through mode, or a size-exclusion chromatography, and c) performing a weak cation exchange chromatography in bind-and-elute mode or flow-through mode, and thereby obtaining the polypeptide in monomeric form. | 05-22-2014 |
| 20140163204 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. | 06-12-2014 |
| 20140323695 | PROTEIN PURIFICATION METHOD - A method for manufacturing an antibody formulation in which DNA contaminants are removed by binding the antibody to a protein-A or probtin-G affinity column and eluting the antibody with an acidic eluting solution, preferably of low conductivity. | 10-30-2014 |
| 20140343252 | INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS - Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells. | 11-20-2014 |
| 20150011732 | POLYMER CONJUGATES OF INTERFERON BETA-1A AND USES - An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications. | 01-08-2015 |
| 20150025223 | System and Method for Producing Interleukin Receptor Antagonist (IRA) - The present invention relates to a system and method for producing high levels of autologous IL-1RA cytokine, comprising: a blood collection vessel ( | 01-22-2015 |
| 20150031859 | USE OF NEW RECOMBINANT INTERFERONS WITH ALTERED SPATIAL CONFIGURATION AND THREE-DIMENSIONAL STRUCTURE - This invention provides a crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-α2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structure model of said interferon useful for drug screening and/or drug design and the mimetic of said interferon. The invention further provides methods of designing and using new recombinant interferons with altered spatial configuration and three-dimensional structure. | 01-29-2015 |
| 20150038678 | Interleukin-10 Polypeptide Conjugates and Their Uses - This invention relates to interleukin-10 (IL-10) polypeptide conjugates comprising at least one non-naturally-encoded amino acid. | 02-05-2015 |
| 20150038679 | Interleukin-3 Polypeptide Conjugates and Their Uses - The disclosure provides methods for targeting interleukin-3 receptor-expressing cells, particularly inhibiting the growth of such cells by using an interleukin-3 (IL-3) variant conjugated to a toxin that will affect cells expressing the interleukin-3 receptor. Further disclosed are interleukin-3 (IL-3) variants comprising one or more non-naturally encoded amino acids, and the structures of non-naturally encoded amino acids. | 02-05-2015 |
| 20150094451 | Readily Isolated Bispecific Binding Molecules with Native Format Having Mutated Constant Regions - The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide having an immunoglobulin constant region where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding of the first and second polypeptides to these affinity reagents. The invention also provides bispecific antibodies that have IgG CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding of the IgG regions to these affinity reagents. The invention also concerns bispecific antibodies which are heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least two amino acids that allow for the isolation of the bispecific antibody based on a differential affinity of one mutated immunoglobulin heavy chain and a second mutated immunoglobulin heavy chain toward two different affinity reagents. | 04-02-2015 |
| 20150105537 | CODON OPTIMIZED SEQUENCE FOR AN ANTIVIRAL PROTEIN - A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in | 04-16-2015 |
| 20150126709 | TRAIL COLLECTIN FUSION PROTEINS - The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications. | 05-07-2015 |
| 20150126710 | FUSION PROTEINS FORMING TRIMERS - The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein. | 05-07-2015 |
| 20150307577 | CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS - The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide. | 10-29-2015 |
| 20150361151 | MACROPHAGE ACTIVATING FACTOR FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising macrophage activating factor (MAF) and method of producing same, particularly to MAF compositions essentially devoid of glycosidase enzymes. The compositions of the present invention and pharmaceutical compositions comprising same are particularly suitable for intravenous administration. | 12-17-2015 |
| 20150374837 | ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN - The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl—)y+x+k] with M=30-300 kDa. | 12-31-2015 |
| 20160031932 | REFOLDING OF PROTEINS - Provided is a method of refolding of recombinant GCSF that minimizes the generation of oxidized forms of GCSF by optimizing the refolding of inclusion bodies containing recombinant GCSF. | 02-04-2016 |
| 20160052983 | Fusion Polypeptides Comprising an Active Protein Linked to a Mucin-Domain Polypeptide - The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention. | 02-25-2016 |
| 20160129129 | IGG4 FC FRAGMENT COMPRISING MODIFIED HINGE REGION - The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate. | 05-12-2016 |
| 20160152730 | Targeted Modified IL-1 Family Members | 06-02-2016 |
| 20160159874 | Targeted Modified TNF Family Members - The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases. | 06-09-2016 |
| 20160159875 | Targeting of Cytokine Antagonists - The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders. | 06-09-2016 |
| 20160177362 | Serum-free Stable Transfection and Production of Recombinant Human Proteins in Human Cell Lines | 06-23-2016 |
| 20170233449 | FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA | 08-17-2017 |
| 20180021696 | AFFINITY CHROMATOGRAPHY WASH BUFFER | 01-25-2018 |
| 20190144518 | THERAPEUTIC IL-13 POLYPEPTIDES | 05-16-2019 |
